Table 2

Combined effect of CYP17 and HSD17B1 high-risk alleles on breast cancer riska startified by stage and by HRT status

Number of high-risk allelesbP (trend)
01234
Controls (n = 508)13943555832353
Stage 1 cases (n = 615)5217623313420
RRc1.001.121.131.11.97
95% CI(0.77–1.63)(0.79–1.63)(0.75–1.64)(0.52–1.81)0.89
Advanced cases (n = 235)1562875813
RRd1.001.331.421.672.21
95% CI(0.73–2.41)(0.79–2.54)(0.91–3.05)(0.98–5.00)0.03
Former and never HRT users
Controls (n = 1025)9029837922236
Advanced cases (n = 147)94055349
RRd1.001.361.471.582.60
95% CI(0.63–2.92)(0.70–3.09)(0.72–3.43)(0.95–7.14)0.09
Current HRT users
Controls (n = 434)451141669217
Advanced cases (n = 82)62231212
RRd1.001.481.431.770.81
95% CI(0.56–3.93)(0.56–3.69)(0.66–4.75)(0.15–4.46)0.58
  • a Age, weight, and ethnicity adjusted.

  • b High risk alleles: CYP17, A2; HSD17B1, A.

  • c Relative risk for stage 1 breast cancer.

  • d Relative risk for advanced breast cancer.